Member Info for CHELSEA7

Not surprised to hear about the behaviour of one poster, must have been embarrassing to hear for those who attended.

I seem to remember two years ago a few were suggesting conflict, but did the question about better communication get any mention?

I was rather hoping it would, but get the feeling the BOD are very mindful of that and have left us less to speculate on. It was Martin Diggle I wanted to meet in particular, but learning my lift was leaving exactly after the AGM I felt I just wanted to spend some time talking to some key people.

So to next year, if all goes well there will be many more than 23 people and hopefully I can travel alone by train. Again thanks to all those for going and your best efforts in getting the recording done to such a high level. Really appreciated that. ATB and have a good day.

Morning all/Chester, feel exactly the same way as you do....I have felt reassured by Vulpes taking that 16.67%. Not only would they have known far more than us but provisions for any further funding would have been as clear as the due diligence they took on Scancell to start with. Financial expertise was the most important addition to the Bod we could have hoped for and we will see that play out in the coming months.

Just reading this BB lately I am very grateful to Bermuda, for his detail, we have had to speculate a lot in the past and I feel with his research, timelines etc we will all benefit from speculations that sometimes do little more than raise expectations to unreasonable levels.

Interesting posts are AGM . Disappointed I missed it a very late change to my plans but run it through a couple who attended and with some info here piecing it together. Shame I wanted to speak to Md and ch after WaRDs.Just 23 attendees must be a record low but a few were on holidays leaving October pretty free
Anyone know what might be the news within six months that wIll drive the Sp on?!

It was not about meeting DE that was the issue, it was purporting to know inside information that is against LSE rules.

Thanks for the recording. Steve and Mia voce too.

I had to cancel last minute, no computer or mobile for a week. Weird experience.

Will catch it later, albeit not the same as going. ATB

Bearing all that in mind and it has been playing on mine the last couple of weeks, I said repeatedly that I understood somes frustration which was fuelled by the IND news, but in all honesty I had and I am pretty sure many others had too, expected the IND to be further delayed. We had a few reiterations as to the problem that existed, and it was frustrating that we couldn"t comment further on the situation as it was an issue between Ichor and the FDA.

My own frustration and disappointment was that we stalled at 10p rather than going through it, during the incredible rise from 3.6p, and further falling back albeit relatively slowly to the 7p level. We cannot blame many for profit taking or slicing after a riselike that but again the volumes weren"t that big, Fridays 4.65% fall was after just 101k shares had been sold and in two trades soon after 95k shares were bought to no movement back in the SP.

That frustration was softened by knowing a buyer was increasing their holdings and taking up the sells derived from our seller, recent news has given thought as to why our buyer was wanting nearly 1m shares a week.

So sentiment for a variety of reasons has been poor on this BB, during a time when good news is landing, and given we rose to 10p on the back of the Vulpes investment, the recent news is deserving of a higher M/Cap than the £34m which with an SP of 7/7.80 we are valued at.

It is my hope that we receive another tem of good news this week before the AGM, but regardless of that I thought we would go into the AGM at around 8p and pass 10p soon after. That is still my hope, considering the very good news from the glycans, news of patient enrolment has that really been priced in???

I would rather avoid my other reasons for the poor sentiment, and wish to apologise to you for getting involved in it, and can assure you that will not happen again, unfortunately the only way I can do that is by filtering a few people, not all for the same reason but Bermuda gave me the best advice of all a few years back reminding me that we cant change people or their agendas, again not all have a bad agenda.

So I hope I have got a few things off my mind this morning and sincerely hope building from ""sentiment starts at home"" we return to that now. I cannot think of another share on AIM where so much patience has been needed, and LTH be rewarded, I also cannot think of a time when Scancell have been in a better position than we are now, with many inflection points coming and a healthy cash position (circa £7m behind us) to build on. IMMHO the glycan news is exceptional and the licensing potential alone could at even £30m pay our expenditure for the next three years, more recruitment and trials in that period too, and believe me if you look at the kind of deals going down now that is a very conservative figure. A blue day coming!! Enjoy yours

Bermuda, further to our conversation yesterday about glycans it was this mention in the H1 Business Update that first reminded me we could well be due news on this platform....................Strengthened IP portfolio

During this period, the Company was granted a US patent that provides protection for Modi-1, the first clinical candidate from Scancell's Moditope® platform, a patent that provides protection for the Moditope® platform in Japan, and a European patent relating to FG88, a monoclonal antibody directed to tumour associated glycans.

Also as far as the SCIB1 trial goes, they gave this information regarding the trial and the U.S. arm of the trial..................

""SCIB1 Phase 2 trial

As reported in April, the Company has received the necessary regulatory and ethical approvals to initiate the UK arm of the SCIB1 clinical trial. Operational activities for clinical centre initiation have been completed and active patient recruitment is anticipated in the coming weeks. The Company continues its dialogue with both Ichor and the FDA with respect to the TriGrid® v2.0 device specific questions and awaits further feedback from the agency with regards to the IND approval which is required to initiate the US arm of the study. The Company will update the market as soon as additional information is available."""

Going back to your list of to do jobs prior to the trial starting, we can presume that from April when we received the European go ahead until July 1st we had indeed been working on the U.K. arm to be ready A.S.AP for trial in the event of the IND not arriving as planned..................."".Operational activities for clinical centre initiation have been completed and active patient recruitment is anticipated in the coming weeks."" I remember saying the comig weeks sounded like 6/7 to me and indeed from the trial enrolment form posted by Steve 67 last week the first patient was recruited on August 19th,""
7 weeks after the coming weeks was stated""

Taking all of this into account and seeing Scancell did all in their power to start both trials as quickly as possible and no time was lost, precious time in starting, I did take the position that I thought the huge disappointment that followed was a bit OTT, and seeing the dates as set out above I find little reason to crucify the BOD as has been done. Sure we are disappointed about the U,S, arm, we knew for a long time there was an issue between Ichor and the FDA but it was not Scancells fault, I just hope for the sake of clarity we get to hear why it was not forthcoming. The SP too plunging from the 7s due to 21m shares from City Financial was again not Scancells fault, we did recover well, and I hope today shows the folly of Fridays 4.65% fall after a 12% gain due to the glycans RNS. Yes, I think we are very undervalued now, lets hope the news has sunk in now. ATB

Again Lindy was ahead of the game with this RNS, just over two years ago, where Scancell and Oncimmune presented autoantibodies data..........................................

Tue, 29th Aug 2017 07:00

RNS Number : 0917P
Scancell Holdings Plc
29 August 2017
29 August 2017

Oncimmune and Scancell Present Data on use of Autoantibodies in Predicting Response to SCIB1 Immunotherapy

EarlyCDT® demonstrates potential to predict disease recurrence

Nottingham, UK - 29 August 2017: Oncimmune Holdings plc (AIM: ONC.L), a leading early cancer detection company developing and commercialising its proprietary EarlyCDT® platform technology, and Scancell Holdings plc, ('Scancell') the developer of novel immunotherapies for the treatment of cancer, today announce the presentation of data on the use of Oncimmune's autoantibody technology to successfully predict disease recurrence in subjects undergoing SCIB1 immunotherapy for malignant melanoma. The data will be presented at the Cambridge Healthtech Institute (CHI) Immuno-Oncology Summit 2017 on August 29 2017."""

The collaborative study, which also included a team at the University of Nottingham, developed a method using a panel of seven tumour associated autoantibodies to predict disease recurrence in patients with resected Stage III/IV melanoma treated with Scancell's SCIB1 immunotherapy. Whilst Phase I/II trials with SCIB1 have been highly encouraging, this additional information potentially enables the identification of patients prior to commencement of therapy who are most likely to respond to treatment in future clinical trials with SCIB1.

Geoffrey Hamilton-Fairley, Chief Executive Officer, commented: "This is the first of a number of companion diagnostics programmes we are undertaking, having shown with internal data that by using Oncimmune's autoantibody platform it is possible to differentiate patient responses to a range of cancer treatments. While validation on a larger data set is necessary, these results indicate that in this case it was possible to identify patients who are most likely to respond to Scancell's SC1B1 and thus further demonstrate the potential of our technology in this application."

Dr Richard Goodfellow, CEO of Scancell added: "If this preliminary data is confirmed in a larger clinical study, it has the potential to improve the design of future clinical trials using SCIB1 by selecting patients most likely to positively respond to our novel treatment and thereby increase the chances of a successful outcome."

Just wonder what part if any has been used in the selection of patients for the current SCIB1 Combo trial. Seems Lindy has utilised a lot of potential studies from companies based in Nottingham University and it is ony good like with Ichor so many of the companies have moved on to success.

Can"t stress it enough chester, the reason why you and nearly all of us find it complicated is because it is. And even Lindys peers find our science and research complicated is because they didn"t come up with it.

What I was trying hard to do last week was remind a few people of our fundamentals and probaly the biggest fundamental is we have Lindy. She chairs and presents at conferences and meetings with the biggest in the industry and even when 2cvguy reminds us how much easier it is to follow a Lindy presentation is because she has worked tirelessly as a clinician in her long career and the best of them can communicate with their parents in such a way they can understand.

I was on one occasion invited to the meeting of oncologists, senior cancer nurses, radiologists. etc etc who meet for 5 hours on a Monday morning discussing every patient who is in hospital or due for an appointment that week to determine the treatment plan for each individual. Often treatments are elected on as there are often more than one course of action that can be taken and that is complicated in itself, let alone understanding the dialogue going on between them. The reason I was there, was ny oncologist wanted me to put my case for not having microwave ablation but cryoblation which they hadn"t used for a year. Microwave ablation had been voted 11 v 2 and for good reasons I had refused it, I one the day and for now that is history, but it felt good and was an honour indeed to sit amongst them.

The complicated nature of what we do, coupled with the share price is IMHO behind the frustration we feel on occasions, as we seem to always be waiting for news and often blind to the timelines needed to get it. Whn we do get news it is often followed in the short term or in the near future which I guess we seize upon as tomorrow and it was on the contributory factors in feeling timelines are often delayed. When we took the glycans and mAbs from the University they could hardly say we will advise you in eighteen months on what has developed for obvious reasons. So either updated seem late or getting into trials do. I am sure it is a difficult balance for Scancell and can only imagine some of the disgruntled mail being sent to the BOD in the last two weeks over the U.S arm when they are sitting on news like the third platorm and can say nothing until it is all signed off. as WTP suggested yesterdaybthey issued that news as soon as they could to appease some sentiment and we hope there will be more to come from the agm.

So remembering our fundamentals is putting our trust in the BOD to turn our potential into commercial success, and I am sure both sides could do something better to achieve a better harmony in respect of that. Looking forward to the trades tomorrow, people have had and the market has had a few more days to digest this news and I expect that to reflect in a fair bit more PI buying.

Obviously, but it will do. I suggested that was the type of RNS that would grow, it is part now of our very fabric. I just wonder if those building a position were half expectant of that and have the appetite for many more. I hope too after the AGM where updates will be discussed on all of our pipeline and with a bit of news more leading up to Thursday the sentiment will change rather dramatically as we restore faith and confidence in the BOD. A funny old thing sentiment it is so changeable, but I do feel this platform, along with patients dosed will take us back into double figures. Take care, catch yer tomorrow.

Glad you posted that 2cv, I think the majority of us can relate to that, but the more we learn it starts falling into place and i Can vouch when you are sitting in the patients chair you can understand better the words and options available to yourself very clearly. I can say with complete certainly oncologists struggle to understand Immunotherapy as the y know what treatments they are working with, what patients they work with, the wards they visit, but simply don"yhave the time to learn what is coming through as alternative treatments, I know from my own team they are attending many seminars and involved in clinical trials that open their eyes to the treatments available and i have seen in the last couple of years a greater understanding amongst them. Put it this way my oncologists always asks me now the progress Scancell are making, music to my ears and if evidence was needed a sign we are breaking through as a stand alone treatment or in combination. Unlike some I elt a big rise was on the cards, only to be very surprised the next day to give up 4.65% of it on just 101k sells.

Confidant as it sinks in we will rise further and will be an interesting day tomorrow for sureYea I find it surprising that we saw just a rise of 8% on the week with that news which frankly goes a long way to ushering in our first commercial deal and validating even further the leadership qualities of LD in Scancell.

With the AGM on Thursday, an interesting week lies ahead, a blue week i feel, and whatever comes out of the AGM i F=feel will put us in an even better place with news the trial has started and first patient/s enrolled. S o lets have a good week and a very interesting AGM

What I am finding is this third platform is so much easier to understand, and once understood makes it easier to grasp the Immnobody and Moditope platforms. I like it.

Night guys

Ruck, yeah good too, felt bad last night.

Bermuda, in direct answer to your question, no I haven"t seen any new articles about the glycans , mAbs and TCR directly linked to Scancell, not so easy to find that information as you well know, lol., but I was saying in a few posts that week that Lindy is up there with the best of them and I expect we will hear news on that front next.

Bermuda, well yes. There has been so much news surrounding glycans and Mabs in articles every day and the commercial deals attached to them. I tend to research what is currently happening in the Oncology world, our appointment of Samantha Paston and the work she did at Adaptimmune and reading back on the University of Nottingham University RNS and have been expecting news on that front for a while.

As far as Vulpes go, well they would have taken into consideration any new rounds of funding needed, there has been a building of holdings in the months since they bought there stake, and we often said the BOD were speaking with some certainty about their plans that funding must have been expected. I believe that applies now too, and we shall here more from the AGM on Thursday. Yes I think we have an excellent chance of seeing a commercial deal from the glycans which could well fund us for expenditure and trials for a few years. Hope that helps.

Afternoon Ruck, just wanted to apologise again for yesterdays misunderstanding, we have never had a disagreement here, and i saw your post addressed to C7 and in a pretty heated moment just presumed it was yet another post directed at me, ATB

Lol, I have said that many times and it is very true. I guess i have put in £28k for my 26k shares, £80 a week sort of, but with circumstances as they have been i just don"t go restaurants and pubs like I did, and from that perspective I feel I am sitting on free shares. The funny thing is that since I bought in I have not spent a penny on any forms of gambling, whether it be lottery tickets, etc etc. So in many ways I have a very different perspective to money. No more buying from me, but as you know my first lady comes from Hungary, and if we are successful here it would sure help in me living half the year there which is what I want to do.

Hi Bermuda, yes I mentioned it about 5/6 times in the week preceding the RNS, I had thought it was coming a couple of months earlier but it was in an effort to argue some very negative posts that we just don"t know at any given time what news might come, There was a few other reasons, which I really don"t want to go into, yesterday was a hideous day for me and this BB, and I have no intention of going there again.

Ratty, I guess that is where it draws a big line between traders and those buying and holding, as we see in daily volumes there are a very small number of trades on a daily basis. Better trading prospects exist in other shares, and the shame of this share is like many other holders we bought in at much higher prices than what we see now. That is frustrating and I think that is what we all feel at different times. Although I didnt lower my average further (15p) it was difficult to say the least watching people buy in at 4/5p where I had at 41p.

For sure. Just been watching the Lindy Durrant presentation, crumbs 07.34, the whole conception of binding the cancer is just so clever. We talk of the advances in the last few years in Oncology, but I cannot remember back in 2012 when many of us bought in here discussing ,let alone them being as advanced as they are now.

Seems like the good people of Hong Kong are demonstrating for a branch to open their too.